Palvella Therapeutics (PVLA) EBITDA Margin (2014 - 2024)
Palvella Therapeutics (PVLA) reported EBITDA Margin of 5150.94% for Q1 2024, down 446112.0% year-over-year from N/an in Q2 2023, and down 7221.07% quarter-over-quarter from 70.36% in Q3 2023.
Palvella Therapeutics (PVLA) EBITDA Margin (2014 - 2024) Analysis & Trends
Palvella Therapeutics (PVLA) has 11 years of EBITDA Margin data on file, last reported at 5150.94% in Q1 2024.
- EBITDA Margin for Q1 2024 came in at 5150.94%, down 446112.0% year-over-year; the trailing twelve-month figure through Sep 2024 was 152.95% (up 23196.0% YoY), and the FY2021 annual result was 159.68%, down 3851.0% from the prior year.
- EBITDA Margin declined to 5150.94% in Q1 2024 per PVLA's latest filing, from 70.36% in the prior quarter.
- Over five years, EBITDA Margin peaked at 21.27% in Q2 2023 and troughed at 5150.94% in Q1 2024.
- A 5-year average of 849.47% and a median of 307.55% in 2022 frame the typical range for EBITDA Margin.
- The sharpest annual moves came in 2023 and 2024: EBITDA Margin surged 374243 bps in 2023, then tumbled 446112 bps in 2024.
- A 5-year view of EBITDA Margin shows it stood at 741.24% in 2020, then surged by 75 bps to 187.69% in 2021, then plunged by 1931 bps to 3812.79% in 2022, then soared by 98 bps to 70.36% in 2023, then slumped by 7221 bps to 5150.94% in 2024.
- Business Quant data shows PVLA's EBITDA Margin at 5150.94% in Q1 2024, 70.36% in Q3 2023, and 21.27% in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Palvella Therapeutics | 1.49 Bn | 1.23 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | -5,150.94% |
| Sep 30, 2023 | -70.36% |
| Jun 30, 2023 | 21.27% |
| Mar 31, 2023 | -689.82% |
| Sep 30, 2022 | -3,812.79% |
| Jun 30, 2022 | -307.55% |
| Mar 31, 2022 | -45.29% |
| Dec 31, 2021 | -187.69% |
| Sep 30, 2021 | -580.45% |
| Jun 30, 2021 | -608.58% |
| Mar 31, 2021 | -28.33% |
| Dec 31, 2020 | -741.24% |
| Sep 30, 2020 | -476.39% |
| Jun 30, 2020 | -42.57% |
| Mar 31, 2020 | -21.33% |
| Dec 31, 2019 | -67.70% |
| Sep 30, 2019 | -3.85% |
| Jun 30, 2019 | -232.73% |
| Mar 31, 2019 | -110.26% |
| Dec 31, 2018 | -1,935.17% |